236 related articles for article (PubMed ID: 35675434)
1. Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression.
Mao C; Yeh S; Fu J; Porosnicu M; Thomas A; Kucera GL; Votanopoulos KI; Tian S; Ming X
Sci Transl Med; 2022 Jun; 14(648):eabh1261. PubMed ID: 35675434
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
[TBL] [Abstract][Full Text] [Related]
4. The interplay between the DNA damage response and ectonucleotidases modulates tumor response to therapy.
Stagg J; Golden E; Wennerberg E; Demaria S
Sci Immunol; 2023 Jul; 8(85):eabq3015. PubMed ID: 37418547
[TBL] [Abstract][Full Text] [Related]
5. Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Perrot I; Michaud HA; Giraudon-Paoli M; Augier S; Docquier A; Gros L; Courtois R; Déjou C; Jecko D; Becquart O; Rispaud-Blanc H; Gauthier L; Rossi B; Chanteux S; Gourdin N; Amigues B; Roussel A; Bensussan A; Eliaou JF; Bastid J; Romagné F; Morel Y; Narni-Mancinelli E; Vivier E; Paturel C; Bonnefoy N
Cell Rep; 2019 May; 27(8):2411-2425.e9. PubMed ID: 31116985
[TBL] [Abstract][Full Text] [Related]
6. Potentiating dual-directional immunometabolic regulation with nanomedicine to enhance anti-tumor immunotherapy following incomplete photothermal ablation.
Jiang Q; Qiao B; Zheng J; Song W; Zhang N; Xu J; Liu J; Zhong Y; Zhang Q; Liu W; You L; Wu N; Liu Y; Li P; Ran H; Wang Z; Guo D
J Nanobiotechnology; 2024 Jun; 22(1):364. PubMed ID: 38915007
[TBL] [Abstract][Full Text] [Related]
7. Syringeable Near-Infrared Light-Activated In Situ Immunogenic Hydrogel Boosts the Cancer-Immunity Cycle to Enhance Anticancer Immunity.
Fu Y; Zhu X; Ren L; Wan J; Wang H
ACS Nano; 2024 Jun; 18(23):14877-14892. PubMed ID: 38809421
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
[TBL] [Abstract][Full Text] [Related]
9. ATP-adenosine axis regulation combined with microneedle assisted photoimmunotherapy to boost the immunotherapy efficiency.
Shi C; Chen M; Li X; Fu Y; Yang D; Wen T; Zhao W; Sun Y; Wang W; Lu C; Wu Q; Wu C; Pan X; Quan G
J Control Release; 2024 Mar; 367():1-12. PubMed ID: 38244844
[TBL] [Abstract][Full Text] [Related]
10. Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer.
Mandapathil M; Szczepanski MJ; Szajnik M; Ren J; Lenzner DE; Jackson EK; Gorelik E; Lang S; Johnson JT; Whiteside TL
Clin Cancer Res; 2009 Oct; 15(20):6348-57. PubMed ID: 19825957
[TBL] [Abstract][Full Text] [Related]
11. CD39 - A bright target for cancer immunotherapy.
Guo S; Han F; Zhu W
Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
Piovesan D; Tan JBL; Becker A; Banuelos J; Narasappa N; DiRenzo D; Zhang K; Chen A; Ginn E; Udyavar AR; Yin F; Paprcka SL; Purandare B; Park TW; Kimura N; Kalisiak J; Young SW; Powers JP; Schindler U; Sivick KE; Walters MJ
Mol Cancer Ther; 2022 Jun; 21(6):948-959. PubMed ID: 35405741
[TBL] [Abstract][Full Text] [Related]
13. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
[TBL] [Abstract][Full Text] [Related]
14. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X; Xie L
J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
[TBL] [Abstract][Full Text] [Related]
15. A nanoparticle-based tour de force for enhancing immunogenic cell death elicited by photodynamic therapy.
Kepp O; Kroemer G
Oncoimmunology; 2022; 11(1):2098658. PubMed ID: 35832042
[TBL] [Abstract][Full Text] [Related]
16. Efficacy-shaping nanomedicine by loading Calcium Peroxide into Tumor Microenvironment-responsive Nanoparticles for the Antitumor Therapy of Prostate Cancer.
Wu D; Zhu ZQ; Tang HX; Shi ZE; Kang J; Liu Q; Qi J
Theranostics; 2020; 10(21):9808-9829. PubMed ID: 32863961
[No Abstract] [Full Text] [Related]
17. Melanin-Based Immunoregulatory Nanohybrids Enhance Antitumor Immune Responses in Breast Cancer Mouse Model.
Guo K; Jiao Z; Zhao X; Hu Y; Zhao N; Xu FJ
ACS Nano; 2023 Jun; 17(11):10792-10805. PubMed ID: 37265256
[TBL] [Abstract][Full Text] [Related]
18. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
[TBL] [Abstract][Full Text] [Related]
19. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
[TBL] [Abstract][Full Text] [Related]
20. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
